Table 1.
Nivolumab monotherapy and combination with ipilimumab efficacy
| Monotherapy | Patients, n | ORR | CR | Median PFS (3 mg/kg) | Median OS | 1-Year OS | 2-Year OS |
|---|---|---|---|---|---|---|---|
| Topalian et al38 | 107 | 31% | NR | 9.7 months | 16.8 months | 62% | 43% |
| Robert et al42 (previously untreated) | 418 | 40% | 7.6% | 5.1 months | Not reached | 73% | NR |
| Weber et al39 (ipilimumab refractory) | 405 | 31.7% | 3.3% | 4.7 months | NR | NR | NR |
|
| |||||||
| Combination therapy | Patients, n* | ORR | CR | Median PFS | Median OS | 1-Year OS | 2-Year OS |
|
| |||||||
| Wolchok et al43 (all dose levels) | 53 | 40% | 9.4% | NR BRAF WT not reached |
NR | NR | NR |
| Postow et al40,44 | 95 | 61% | 22% | BRAF mut 8.5 months | Not reached | 73% | 64% |
| Larkin et al41 | 314 | 57.6% | 11.5% | 11.5 months | Not reached | NR | NR |
Note:
*
Receiving concurrent ipilimumab + nivolumab.
Abbreviations: ORR, objective response rate; CR, complete response; PFS, progression-free survival; OS, overall survival; NR, not reported; WT, wild type.